We conducted a case-control study to determine the attributable direct costs of multidrug-resistant Acinetobacter baumannii (MDRAB) in the burn unit of a public teaching hospital. The mean total hospital cost of patients who acquired MDRAB was 98,575 dollars higher than that of control patients who had identical burn severity of illness indices ( P <.01). These data should help infection control practitioners and others determine the cost-effectiveness of specific interventions designed to control this emerging nosocomial pathogen.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ajic.2004.02.008 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!